Participated · Equity · Jul 2026

Founded in 2018 and based on the CNRS campus in Montpellier, Womed develops intravaginal/intrauterine polymer-based treatments for women's health. Its FDA-approved device Womed Leaf is intended to prevent intrauterine adhesions and the company reports about 2,000 women helped to date with a target of 95,000 women treated per year by 2028. Eynia is an investigational, gynecologist-administered biodegradable polymer treatment for fibroids that blocks progesterone for three months before degrading, and is planned to enter phase II trials. Womed says it aims to expand into treatments for acute bleeding and endometriosis. The company employs ten people and works with a similar number of consultants, including Dr André Ulmann. Financially, Womed recently raised €5 million from institutional investors, is running €1 million in public crowdfunding, and had previously raised €6 million in 2024.

Participated · Series A · Jul 2026

Founded in 2020 in Toulouse, Bohr Énergie operates a proprietary platform that combines software, AI, algorithms, production forecasting, market analysis and regulatory expertise to enable optimisation and commercialisation of distributed renewable and flexible assets. As an independent aggregator it manages solar, wind, hydro, batteries and hybrid systems, enabling asset owners to participate in electricity markets. The firm currently has more than 170 renewable and flexible assets in its portfolio and expects to reach close to 1 GW under management by the end of the year. Management plans to use the Series A capital to consolidate its French position, accelerate platform development and launch additional services. Bohr has signalled international expansion with Spain and Italy among its priority markets.

Participated · Equity · May 2026

Founded in 2022 and based in Montpellier, ThIA Santé Mentale develops a coordinated model of care in mental health that pairs digital and organizational solutions with clinical partners. The company positions itself in psychiatry, working with practitioner partners to deliver coordinated care pathways. In May 2026 it secured a €5M funding round led by institutional and insurance investors to scale that model. Investors in the round include IRDI Capital Investissement, Sofilaro Innovation, Generali, AG2R La Mondiale, and participating individual and practitioner investors. The stated use of proceeds is to extend and scale its coordinated care offering. The articles do not provide revenue, user metrics, or a valuation.

Led · Equity · Apr 2026

Donecle offers a patented inspection system that combines autonomous drones, high-resolution imaging and AI to automate aircraft inspections, which the company says can be completed up to 10x faster than manual methods. Its platform is certified by Airbus, Boeing, the European Union Aviation Safety Agency and the U.S. Federal Aviation Administration and is deployed in more than 15 countries with a fleet of over 40 drones. Customers include commercial and military operators such as United, LATAM, DHL, Viva, Lufthansa, the French Air Force and the Royal Air Force. Donecle reports that its drone operations have saved several thousand tonnes of CO2eq by replacing diesel-powered aerial work platforms and reducing aircraft downtime. The company has a team of 35 employees and plans to hire around ten more staff following the recent financing. With the new funds it intends to accelerate international expansion, pursue partnerships and acquisitions, and continue investing in AI and data integration with MRO systems.

Participated · Equity · Mar 2026

DiappyMed builds a digital therapy designed to personalize insulin dose calculations for people with type 1 or type 2 diabetes treated with a basal/bolus regimen. The company presents its solution as the first French therapy numérique dedicated to individualized insulin dosing and says it works with professionals de santé and patients. DiappyMed announced a strategic partnership with Sanofi to enable broad deployment of the therapy across France. The company aims to secure reimbursement from Assurance Maladie by 2026 and frames the recent financing and partnership as steps toward that objective. In support of its rollout, DiappyMed raised €5 million in an amorçage round led by Ventech and AFI Ventures with participation from SOFILARO/CALEN and IRDI Capital Investissement, and cited additional institutional partners and supporters. No revenue, user metrics, founding year, or valuation were disclosed in the available articles.